Page 50 - Bioterrorism
P. 50

49


               Journal of American Physicians and Surgeons Volume 11 Number 1 Spring 2006

               http://www.drbriffa.com/blog/2007/02/19/world-health-organisation-accused-of-improper-
               soliciting-of-funds-from-the-pharmaceutical-industry/
               World Health Organisation accused of improper soliciting of funds from the pharmaceutical
               industry
               Posted on 19 February 2007
               It seems that not a week goes by without some information leaking out about the sometimes too-
               cosy relationship that can exist between the pharmaceutical industry and organisations we rely on
               for giving us impartial health information and advice. This particular week’s story concerns
               accusations that a representative of the World Health Organisation (WHO) attempted to solicit
               funds from the pharmaceutical company GlaxoSmithKline, and then siphon them through an
               organisation to obscure the source of the those funds.
               The individual at the centre of this controversy is Dr Benedetto Saraceno, director of the WHO’s
               department of mental health and substance abuse. It is alleged that he was seeking £5000
               ($10,000; 7000 euros) to pay for the preparation for a report on neurological diseases including
               Parkinson’s disease. The WHO has a strict policy that forbids it from taking funds from the
               pharmaceutical industry, and quite right so.
               However, in an email that has been passed to the British Medical Journal, Dr Saraceno appears to
               suggest that to get around this, money from GSK should be paid to an organisation known as the
               European Parkinson’s Disease Association (EPDA). In an email to the EPDA, Dr Saraceno writes
               “WHO cannot receive funds from the pharmaceutical industry,” and goes on to add “I suggest that
               this money should be given to EPDA and eventually EPDA can send the funds to WHO which
               will give and invoice (and acknowledgment contribution) to EPDA but not to GSK.”
               It is alleged that GSK promptly withdrew its offer once it became clear they would not be
               officially recognised as the source of this funding.
               Since the somewhat—damning correspondence came to light, it seems that Dr Saraceno has
               attempted to do some major backtracking. He claims that his original email to EPDA was
               “clumsily worded” and that he denied ever suggesting that funds from GSK be siphoned through
               the EPDA. Personally, I find it hard to imagine what it is about the wording of Dr Saraceno’s
               email to the EPDA that is in any way clumsy. And neither does Mary Baker - the person at the
               EPDA to whom Dr Saraceno was writing. She is quoted as saying “There is absolutely no doubt
               in my mind that Dr Saraceno knew the $10,000 was coming from GSK and that he was intending
               to take it and disguise its origins by getting EPDA to accept it first before passing it on.”
               When the BMJ put its concerns about this rather distasteful episode to the WHO, a spokesman
               apparently replied “It’s astonishing that the BMJ thinks there’s a story here. Dr Saraceno sent a
               second email saying he had not meant to ask for the money. So I don’t think there’s anything to
               answer.” Does the WHO really believe that just because one of its employees denies impropriety,
               even when presented with evidence that appears to suggest otherwise, that there is no case to
               answer? I have a feeling that many who learn of this sorry state of affairs would beg to differ.
               References:
               1. Day M. Who’s funding WHO? British Medical Journal 2007;334:338-340



               X. Evidence Novartis is using vaccines as bioweapons.



               The bird flu trials conducted by Novartis in 2008 offers evidence that companies are designing
               their trials of pandemic flu vaccines for adverse events, that is, for disease and death.
   45   46   47   48   49   50   51   52   53   54   55